Successful Completion Of The Project NaDiNa

Within medac CDMO, the NaDiNa project represented a collaborative effort to advance a novel anticancer drug from formulation through prototype production, setting the stage for clinical evaluation. Conducted alongside the Faculty of Medicine at Palacky University (UPOL) and supported by the Technology Agency of the Czech Republic (TAČR), the project focused on translating cutting-edge research into a viable medicinal product.

The NaDiNa drug candidate is a nanotechnology-based formulation of the copper salt of diethyldithiocarbamate (CuET) using albumin as a carrier for intravenous administration. It targets solid tumors and hematological malignancies through selective binding to the protein NPL4, inducing proteotoxic stress and cancer cell death. Preclinical studies led by UPOL optimized nanoparticle stability, evaluated pharmacokinetics and toxicity, and demonstrated selective cytotoxicity, including against chemotherapy-resistant tumor cells.

On the CDMO side, medac developed the formulation, established and optimized the manufacturing process under GMP conditions, produced a clinical batch, and implemented analytical and technical documentation to ensure reproducibility and regulatory readiness. The project culminated in official approval by TAČR, highlighting the integration of academic research with industrial capabilities.

Discover how medac CDMO bridges scientific innovation and industrial execution to accelerate the development of next-generation therapeutics.